Literature DB >> 21986263

Updated staging system for lung cancer.

Peter Goldstraw1.   

Abstract

The seventh edition of TNM for Lung Cancer came into effect on the first of January 2011. Containing more than 100,000 cases of lung cancer treated by all modalities of care and from around the world, this is the largest database ever accumulated for this purpose. This edition allows detailed analysis and intensive validation such that the resultant classification aligns stage with prognosis more closely than ever before. There have been changes to certain tumor and metastasis descriptors and the resultant stage groupings. This article describes these changes, provides more in-depth discussion of the changes, and provides much additional information. 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21986263     DOI: 10.1016/j.soc.2011.07.005

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  22 in total

1.  C6orf106 enhances NSCLC cell invasion by upregulating vimentin, and downregulating E-cadherin and P120ctn.

Authors:  Xiupeng Zhang; Yuan Miao; Xinmiao Yu; Yong Zhang; Guiyang Jiang; Yang Liu; Juanhan Yu; Qiang Han; Huanyu Zhao; Enhua Wang
Journal:  Tumour Biol       Date:  2015-03-04

2.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

3.  Zinc finger protein 668 suppresses non-small cell lung cancer invasion and migration by downregulating Snail and upregulating E-cadherin and zonula occludens-1.

Authors:  Xiupeng Zhang; Guiyang Jiang; Jingjing Wu; Haijing Zhou; Yong Zhang; Yuan Miao; Yangyang Feng; Juanhan Yu
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

4.  Overexpression and cytoplasmic accumulation of Hepl is associated with clinicopathological parameters and poor prognosis in non-small cell lung cancer.

Authors:  Yuan Miao; Liang Wang; Yang Liu; Ai-Lin Li; Shu-Li Liu; Hong-Yi Cao; Xiu-Peng Zhang; Gui-Yang Jiang; Di Liu; En-Hua Wang
Journal:  Tumour Biol       Date:  2012-09-23

5.  Overexpression of CASS4 promotes invasion in non-small cell lung cancer by activating the AKT signaling pathway and inhibiting E-cadherin expression.

Authors:  Ailin Li; Weiwei Zhang; Huifang Xia; Yuan Miao; Haijing Zhou; Xiupeng Zhang; Qianze Dong; Qingchang Li; Xueshan Qiu; Enhua Wang
Journal:  Tumour Biol       Date:  2016-09-27

6.  Overexpression of NEDD9 is associated with altered expression of E-Cadherin, β-Catenin and N-Cadherin and predictive of poor prognosis in non-small cell lung cancer.

Authors:  Yuan Miao; Ai-Lin Li; Liang Wang; Chui-Feng Fan; Xiu-Peng Zhang; Hong-Tao Xu; Lian-He Yang; Yang Liu; En-Hua Wang
Journal:  Pathol Oncol Res       Date:  2012-10-20       Impact factor: 3.201

7.  Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer.

Authors:  Ke Xu; Bin Liu; Yongyu Liu
Journal:  Mol Med Rep       Date:  2015-02-13       Impact factor: 2.952

8.  Impact of p120-catenin isoforms 1A and 3A on epithelial mesenchymal transition of lung cancer cells expressing E-cadherin in different subcellular locations.

Authors:  Yijun Zhang; Yue Zhao; Guiyang Jiang; Xiupeng Zhang; Huanyu Zhao; Junhua Wu; Ke Xu; Enhua Wang
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

9.  Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.

Authors:  Yuan Miao; Liang Wang; Xiupeng Zhang; Xiaohan Xu; Guiyang Jiang; Chuifeng Fan; Yang Liu; Xuyong Lin; Juanhan Yu; Yong Zhang; Enhua Wang
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

10.  Lung cancer: changes in histology, gender, and age over the last 30 years in Brazil.

Authors:  Maria Teresa Ruiz Tsukazan; Álvaro Vigo; Vinícius Duval da Silva; Carlos Henrique Barrios; Jayme de Oliveira Rios; José Antônio de Figueiredo Pinto
Journal:  J Bras Pneumol       Date:  2017 Sep-Oct       Impact factor: 2.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.